(27 Apr 2021) Azithromycin- adding AZT to SOC did not reduce the risk of hospitalization or death

A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

https://www.medrxiv.org/content/10.1101/2021.04.21.21255807v1

NCT04381962- 298 participants were enrolled from 3^rd June 2020 to 29^th January 2021. The primary outcome was assessed in 292 participants. The primary endpoint was not significantly different between the azithromycin and control groups (Adjusted OR 0·91 [95% CI 0·43-1·92], p=0·80). Rates of respiratory failure, progression to pneumonia, all-cause mortality, and adverse events, including serious cardiovascular events, were not significantly different between groups. In patients with mild-moderate COVID-19 managed without hospital admission, adding azithromycin to standard care treatment did not reduce the risk of subsequent hospitalisation or death.